Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients

The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients.

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01224327

Enrollment

Registered

2010-10-20

Start date

2010-10-31

Completion date

2012-12-31

Last updated

2010-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Mesenchymal Stem Cells, Radiology, Umbilical Cord

Keywords

Liver cirrhosis, Radiology, Mesenchymal Stem Cells, Umbilical Cord

Brief summary

The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis.

Detailed description

To investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis. Patients with liver cirrhosis were randomly separated into two groups. Umbilical cord MSCs were infused to patients using interventional method via hepatic artery for One group. After the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord MSCs were infused slowly for 15-20minutes. The control group accepted conserved therapy.

Interventions

BIOLOGICALumbilical cord Mesenchymal Stem Cells

Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.

DRUGConserved therapy

Oral or intravenous administration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Aged 18\ 70 years. * Liver cirrhosis * written consent

Exclusion criteria

* The end-stage of liver cirrhosis. * Severe problems in other vital organs(e.g.the heart,renal or lungs). * Hepatocellular carcinoma or other malignancies * Pregnancy * sepsis * Presence of significant extrahepatic biliary disease (e.g. CBD stone, PSC, etc.) * Cardiac, renal or respiratory failure * Active thrombosis of the portal or hepatic veins

Design outcomes

Primary

Measure	Time frame
The result of liver function and liver histological improvement.	every 4 weeks

Secondary

Measure	Time frame
The disappearance or reduction of abdominal dropsy	every 4 weeks
The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs )	every 4 weeks

Countries

China

Contacts

Primary ContactJianxia Hu, MD

qdyxyhjx@126.com86-0532-82911676

Backup ContactHong Gao, MS

honggaogloria@gmail.com86-0532-82911676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026